|
'A new frontier:' US FDA approves Novartis' $475,000 CAR-T cell cancer therapy
Kymriah (tisagenlecleucel), made at the former-Dendreon site in New Jersey, has become the first gene modified cell therapy to be approved in the US… Read
Gilead aims to expand CAR-T manufacturing capabilities post-Kite acquisition
Gilead says it is committed to driving down costs of CAR-T manufacturing after agreeing to buy late-stage cell and gene therapy firm KitePharma for $11.9bn… Read
Dude where's my CAR-T? Personalised meds need personalised logistics, says TrakCel
Real-time production and high-value product pressures means CAR-T cell therapy makers must not underestimate the complexity of the supply chain, says logistics firm TrakCel… Read
CAR-T before the bourse: Kymriah OK will ease fundraising but price an issue says ISCT
US approval for Novartis's CAR-T cancer treatment Kymriah will help cell and gene therapy firms attract the investors they need to fund development according to International Society for Cellular Therapy (ISCT)… Read
Oxford BioMedica could pocket $100m on Novartis CAR-T cell success
Oxford BioMedica saw its share price jump 21% after the US FDA approved Kymriah, the gene modified cell therapy made with the firm's lentiviral vectors… Read
Being for the $11.9bn benefit of investors of Kite: Gilead jumps into CAR-T
Gilead will add a late-stage CAR T-cell candidate and a facility in California capable of treating 5,000 patients per year through the $11.9bn deal… Read
|
